News
Important Only
Dentsply Sirona Inc - Appoints Michael Pomeroy As Interim CFO - SEC Filing
Nov 25 (Reuters) - DENTSPLY SIRONA Inc XRAY.O:DENTSPLY SIRONA INC - APPOINTS MICHAEL POMEROY AS INTERIM CFO - SEC FILINGDENTSPLY SIRONA INC - DANIEL T. SCAVILLA CONTINUES AS PRINCIPAL FINANCIAL OFFICER - SEC FILINGSource text: [ID:n0000818479-25-000281]Reuters
18 hours ago
MF International Announces Executive Transition As Company Launches Digital Asset Treasury Strategy
Nov 25 (Reuters) - mF International Limited MFI.O:MF INTERNATIONAL ANNOUNCES EXECUTIVE TRANSITION AS COMPANY LAUNCHES DIGITAL ASSET TREASURY STRATEGYMF INTERNATIONAL LIMITED - HAOYU WANG RESIGNS AS CEO, DIRECTOR, AND CCOMF INTERNATIONAL LIMITED - DAWEI YUAN APPOINTED AS CEO OF MF INTERNATIONALReuters
18 hours ago
Fusion Fuel’S Brighthy Solutions Expands Green Hydrogen Footprint In Southern Europe
Nov 25 (Reuters) - Fusion Fuel Green PLC HTOO.O:FUSION FUEL’S BRIGHTHY SOLUTIONS EXPANDS GREEN HYDROGEN FOOTPRINT IN SOUTHERN EUROPE WITH AGREEMENT TO DELIVER NEW ELECTROLYZER AND HYDROGEN REFUELING STATION PROJECTFUSION FUEL GREEN PLC - CONTRACT VALUED AT €1.7 MILLION FOR ELECTROLYZER AND REFUELING...Reuters
18 hours ago
Jayud Global Logistics Assumes Controlling Interest In Longgang Cross-Border E-Commerce Center
Nov 25 (Reuters) - Jayud Global Logistics Ltd JYD.O:JAYUD GLOBAL LOGISTICS ASSUMES CONTROLLING INTEREST IN LONGGANG CROSS-BORDER E-COMMERCE CENTERJAYUD GLOBAL LOGISTICS LTD - BUYS CONTROLLING 52% STAKE IN LONGGANG CENTERReuters
18 hours ago
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results
Nov 25 (Reuters) - Anavex Life Sciences Corp AVXL.O:ANAVEX LIFE SCIENCES REPORTS FISCAL 2025 FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEANAVEX LIFE SCIENCES CORP QTRLY EPS $-0.11ANAVEX LIFE SCIENCES CORP: ANTICIPATES AT ITS CURRENT CASH UTILIZATION RATE, APPROXIMATE CASH RUNWAY OF ...Reuters
18 hours ago
Bos Continues Record Year Performance In Q3 2025, Sales Increase 16% Year-Over-Year
Nov 25 (Reuters) - BOS Better Online Solutions Ltd BOSC.O:BOS CONTINUES RECORD YEAR PERFORMANCE IN Q3 2025, SALES INCREASE 16% YEAR-OVER-YEARBOS 9M EPS USD 0.43BOS 9M PRETAX PROFIT USD 2.978 MILLIONBOS 9M REVENUE USD 37.945 MILLIONBOS 9M GROSS PROFIT USD 9.053 MILLIONBOS 9M NET INCOME USD 2.792 MILL...Reuters
18 hours ago
Abercrombie & Fitch Co. Reports Third Quarter Fiscal 2025 Results
Nov 25 (Reuters) - Abercrombie & Fitch Co ANF.N:ABERCROMBIE & FITCH CO. REPORTS THIRD QUARTER FISCAL 2025 RESULTSABERCROMBIE & FITCH Q3 SALES USD 1,290.619 MILLION VS. IBES ESTIMATE USD 1,274 MILLIONABERCROMBIE & FITCH Q3 NET INCOME USD 115.1 MILLIONABERCROMBIE & FITCH CO: TIGHTL...Reuters
19 hours ago
Veralto Announces Agreement To Acquire In-Situ And Establishes $750 Million Share Buyback
Nov 25 (Reuters) - Veralto Corp VLTO.N:VERALTO ANNOUNCES AGREEMENT TO ACQUIRE IN-SITU AND ESTABLISHES $750 MILLION SHARE REPURCHASE PROGRAMVERALTO CORP - TO BUY IN-SITU FOR $435 MILLIONVERALTO CORP - ESTIMATED $11 MILLION COST SYNERGIES BY YEAR THREE AFTER DEAL CLOSEReuters
19 hours ago
Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Nov 25 (Reuters) - Autolus Therapeutics PLC 6A3Ay.F:NICE RECOMMENDS AUCATZYL® (OBECABTAGENE AUTOLEUCEL) AS A TREATMENT OPTION FOR ADULT PATIENTS (≥26 YEARS) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)¹AUTOLUS THERAPEUTICS PLC - PLANS IMMINENT LAUNCH OF AUCAT...Reuters
19 hours ago
Zim Bod Updates On Ongoing Strategic Review Process
Nov 25 (Reuters) - ZIM Integrated Shipping Services Ltd 2SV.F:ZIM BOD UPDATES ON ONGOING STRATEGIC REVIEW PROCESSZIM: GOT INDICATIONS OF INTEREST FROM MULTIPLE PARTIES, INCLUDING STRATEGIC INTEREST, WHICH IT IS EVALUATING CAREFULLYReuters
19 hours ago
US FDA approves Novartis' gene therapy for rare muscle disorder
By Sriparna Roy and Bhanvi SatijaNov 24 (Reuters) - The U.S. Food and Drug Administration has approved Novartis' NOVN.S gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday. The therapy, branded as Itvisma, was approved for the treatment of spinal muscular atrophy...Reuters
19 hours ago
Kohl's Q3 Net Sales USD 3,407 Million Versus. Ibes Estimate USD 3,329 Million
Nov 25 (Reuters) - Kohls Corp KSS.N:KOHL'S Q3 NET SALES USD 3,407 MILLION VERSUS. IBES ESTIMATE USD 3,329 MILLIONKOHL'S Q3 GROSS MARGIN 39.6%KOHL'S Q3 EBIT USD 73 MILLIONKOHL'S Q3 NET INCOME USD 8 MILLIONKOHL'S Q3 PRETAX PROFIT USD -2 MILLIONKOHL'S Q3 EPS USD 0.07KOHLS: OUTLO...Reuters
19 hours ago
Movado Group, Inc. Announces Third Quarter Fiscal 2026 Results
Nov 25 (Reuters) - Movado Group Inc MOV.N:MOVADO GROUP, INC. ANNOUNCES THIRD QUARTER FISCAL 2026 RESULTSMOVADO Q3 PRETAX PROFIT USD 12.936 MILLIONMOVADO Q3 GROSS PROFIT USD 101.056 MILLIONMOVADO Q3 NET INCOME USD 9.661 MILLIONMOVADO Q3 SALES USD 186.132 MILLIONMOVADO GROUP INC: NOT PROVIDING FISCAL ...Reuters
19 hours ago
J.M. Smucker Outlook FY Adjusted EPS USD 8.75-9.25
Nov 25 (Reuters) - J M Smucker Co SJM.N:J.M. SMUCKER OUTLOOK FY ADJUSTED EPS USD 8.75-9.25J.M. SMUCKER Q2 ADJUSTED EPS USD 2.1 VERSUS. IBES ESTIMATE USD 2.1J.M. SMUCKER Q2 EPS USD 2.26J.M. SMUCKER Q2 ADJUSTED OPERATING INCOME USD 394.3 MILLION VERSUS. IBES ESTIMATE USD 384.2 MILLIONJ.M. SMUCKER Q2 S...Reuters
19 hours ago
Best Buy Outlook FY Adjusted EPS USD 6.25-6.35
Nov 25 (Reuters) - Best Buy Co Inc BBY.N:BEST BUY OUTLOOK FY ADJUSTED EPS USD 6.25-6.35BEST BUY OUTLOOK FY REVENUE USD 41,650-41,950 MILLIONBEST BUY Q3 REVENUE USD 9,672 MILLION VERSUS. IBES ESTIMATE USD 9,559 MILLIONBEST BUY Q3 NET INCOME USD 140 MILLIONBEST BUY Q3 GROSS PROFIT USD 2,248 MILLIONBES...Reuters
19 hours ago
Person suspected of being fourth member of Louvre robbery gang has been arrested -Le Parisien
PARIS, Nov 25 (Reuters) - A person suspected of being the fourth member of the main gang that robbed the Louvre last month has been arrested, reported Le Parisien paper on Tuesday.The daylight robbery, in which four robbers made off with jewels worth $102 million, raised doubts over the credibility ...Reuters
19 hours ago
